Paradigm Asset Management CO LLC Nektar Therapeutics Transaction History

Paradigm Asset Management CO LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$15.77 - $19.03 $30,751 - $37,108	-1,950 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$16.86 - $23.44 $32,877 - $45,708	1,950 New	1,950 $45,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $18,258 - $33,990	-600 Closed	0 $0
Q3 2018 Nov 19, 2018	BUY	$46.46 - $68.49 $6,969 - $10,273	150 Added 33.33%	600 $0
Q4 2017 Feb 12, 2018	SELL	$23.02 - $60.5 $64,456 - $169,400	-2,800 Reduced 86.15%	450 $0
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $57,817 - $78,000	3,250	3,250 $0

146

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $197M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Paradigm Asset Management CO LLC, based on Form 13F filings with the SEC.

Stay updated on Paradigm Asset Management CO LLC with notifications on news.